JeanChristophe Tellier - UCB SA Insider

UCBJY -- USA Stock  

USD 38.45  0.000001  0.00%

Chairman of the Executive Committee, CEO

Mr. JeanChristophe Tellier has served as Chairman of the Executive Committee, Chief Executive Officer, Executive Director of UCB S.A. since January 1, 2015. Before that, he was Member of the Executive Committee, Executive Vice President and President of European Operations of the Company from July 1, 2011. He joined the Company from Ipsen where he was President General Manager Ipsen US. His role at Ipsen was to strengthen Ipsen specialty care business in North America, in the areas of endocrinology and neurology. He joined Ipsen in May 2009. He started his career in 1988 in the marketing department of Synthelabo and joined Ciba France as Group Marketing Manager in 1990 and got various marketing sales position until leading the Marketing Sales department. In 1997, following the merger of Ciba and Sandoz to form Novartis, he was appointed Head of the Mass Market Business unit in France until the end of 1999 where he became Chief Operating Officer of Novartis France. From 2003 to mid2006, JC Tellier was Chief Executive Officer of Novartis Pharma Belgium and during his tenure was elected president of Pharma.be, the Pharma trade association. At the end of 2006, he was promoted to Head of the Global Arthritis, Bone and Muscle disease Business Franchise at Novartis Headquarters in Basel, Switzerland. In February 2007, he was appointed Chairman and CEO of Novartis Pharma France and Novartis Group France until mid 2008 when he decided to join MacroGenics Inc., a Marylandbased biotechnology company, as Executive Vice President and Chief Commercial Officer. He is physician specialized in rheumatology and followed diverse executive training both at INSEAD and Harvard.
Age: 58  Chairman Since 2015      
32 2 559 99 99  http://www.ucb.com

Management Efficiency

The company has return on total asset (ROA) of 6.67 % which means that it generated profit of $6.67 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 13.73 % meaning that it generated $13.73 on every $100 dollars invested by stockholders.
The company has accumulated 1.82 B in total debt with debt to equity ratio (D/E) of 27.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. UCB SA has Current Ratio of 1.34 which is within standard range for the sector.

Similar Executives

Entity Summary

UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. UCB SA was founded in 1928 and is based in Brussels, Belgium. UCB SA operates under Biotechnology classification in USA and traded on OTC Market. It employs 7478 people.UCB SA (UCBJY) is traded on OTC Market in USA. It is located in All?e de la Recherche, 60 and employs 7,478 people.

UCB SA Leadership Team

Pascale Richetta, President
Detlef Thielgen, CFO
Kay Davies, Director
Dirk Teuwen, VP
Anna Richo, EVP
Viviane Monges, Director
Gerhard Mayr, Chairman
Cyril Janssen, Director
Cedric Rijckevorsel, Director, CFA
JeanChristophe Tellier, Chairman
Arnoud Calesberg, Director
Mark McDade, COO
Xavier Michel, President
Dhavalkumar Patel, President
Bharat Tewarie, President, MBA
Roch Doliveux, Chairman
Norman Ornstein, Director
Jeff Wren, President
JeanPierre Kinet, Director, Ph.D
Antje Witte, VP
Alice Dautry, Director
Harriet Edelman, Director, MBA
Ulf Wiinberg, Director
Thomas McKillop, Director, Ph.D
Charl Zyl, President
France Nivelle, VP
Fabrice Enderlin, President
Pierre Gurdjian, Director
Ismail Kola, EVP, Ph.D
Emmanuel Caeymaex, President
Evelyn Bergendal, Executive
Iris LoewFriedrich, President, Ph.D
CharlesAntoine Janssen, Director
Albrecht Graeve, Director
JeanLuc Fleurial, President
Alexander Moscho, President

Stock Performance Indicators

Current Sentiment - UCBJY

UCB SA Investor Sentiment
Macroaxis portfolio users are unemotional in their outlook on investing in UCB SA. What is your outlook on investing in UCB SA? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip
Also Currentnly Active
Purchased over 100 shares of
over a week ago
Traded for 10.44
Purchased over 300 shares of
over a week ago
Traded for 6.24
Purchased over 70 shares of
over a week ago
Traded for 23.42
Also please take a look at World Market Map. Please also try Portfolio Quick Import module to import or update all your transactions via one easy-to-use interface.